Target the source of your IgA Nephropathy (IgAN).
IgA Nephropathy (IgAN) is a rare, chronic kidney disease that can slowly damage the kidney leading to organ failure and require dialysis or transplant. Managing IgAN can be challenging—sometimes overwhelming.
Vera Therapeutics is a biotechnology sponsor that is conducting a clinical study with atacicept. The ORIGIN study is exploring how atacicept, the study medication, might help people with IgAN by reducing the source of what causes IgAN, overproduction of an abnormal antibody called galactose-deficient IgA1 (Gd-IgA1). By reducing Gd-IgA1, this in turn can reduce the production of autoantibodies against Gd-IgA1, lowering immune complex formation. With less immune complex deposition in the kidneys, inflammation and damage would also be reduced on the blood filters in the kidney. What researchers learn from the study could help you and other people with IgAN in the future.
If you’re interested in helping researchers learn more about a possible therapy for IgAN, consider joining the ORIGIN clinical research study.